| Jul 5 |
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
|
| Jun 13 |
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
|
| Jun 6 |
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
|
| Jun 6 |
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
|
| Jun 5 |
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
|
| May 29 |
Arbutus to Participate in Jefferies Global Healthcare Conference
|
| May 22 |
Arbutus to Present Imdusiran Data at EASL Congress 2024
|
